Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab

Journal of Viral Hepatitis, 06/12/2012

No beneficial effects of RTX were evidenced on liver fibrosis progression, but authors found interesting correlations with the serum albumin level, FibroTest values and B–cell count.

Print Article Summary Cat 2 CME Report